Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PBSC-M87o
- Development stage
- Unknown
- Lead developer
- University Medical Center Hamburg-Eppendorf
- Modality
- Gene Silencing → Gene Therapies, Stem Cell Therapies → Cell Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
PBSC-M87o is an investigational gene-modified cell therapy developed by the University Medical Center Hamburg-Eppendorf. It consists of autologous (or allogeneic) CD34+ hematopoietic progenitor/stem cells that have been transduced with the M87o lentiviral vector. This vector encodes an anti-HIV gene construct designed to confer resistance to HIV infection in the engrafted stem cells and their differentiated progeny. The therapy was primarily evaluated in HIV-positive patients with hematologic malignancies, such as AIDS-related lymphoma, who required hematopoietic stem cell transplantation. In clinical trials, these modified cells were used as a rescue treatment following high-dose chemotherapy to provide a source of HIV-resistant immune cells, aiming to assess safety, toxicity, and potential anti-tumor and anti-HIV effects.
- Other names
- Gene (M87o)-modified, CD34+ peripheral blood progenitor cellsM87o-transduced CD34+ cellsM87o-modified hematopoietic stem cellsM-87o-modified hematopoietic stem cellsM 87o-modified hematopoietic stem cells
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on PBSC-M87o.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PBSC-M87o.